Products - Daiichi Sankyo
WEBENHERTU (5.4 mg/kg) is approved in more than 60 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+ or in-situ hybridization (ISH)+) breast cancer who have received a prior anti-HER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have develo...
Products - Daiichi Sankyo US
WEBDaiichi Sankyo is dedicated to creating new standards of care by leveraging our world-class science and technology. We currently have three innovative oncology medicines approved in the U.S. to treat certain patients with breast, lung and gastric cancer as well as acute myeloid leukemia and tenosynovial giant cell tumor.
Passion for Innovation. - Daiichi Sankyo US
WEBOur collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges. Caring for a Cancer Patient, I Learned My Craft—Listening.
Caring for a Cancer Patient, I Learned My Craft—Listening
WEBAug 13, 2024 · Simon’s Craft is Listening. I was 16 when I learned the difference between listening with my ears and listening with my heart. I was working as a volunteer at a hospital—serving food, cleaning and making beds—and I spent a lot of time with patients.
Daiichi Wins FLOXIN® Otic Patent Challenge by Generic ... - Daiichi Sankyo
WEBAug 3, 2006 · FLOXIN® Otic is the first antibiotic ear drop medicine ever approved by the FDA for treating bacterial ear infections in pediatric and adult patients with a perforated eardrum.
NHS England to offer Daiichi Sankyo’s quizartinib for AML
WEB1 day ago · In this article: 4568.T. The National Health Service (NHS) England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML) patients with the FLT3 ...
Daiichi Sankyo - Wikipedia
WEBDaiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. [3]
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
WEB4 days ago · The sixth ADC candidate is DS-3939, a TA-MUC1-directed ADC, which Daiichi Sankyo is developing on its own. Pfizer PFE also has a strong portfolio of ADC drugs, which were added with last year’s ...
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main …
WEB4 days ago · Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Daiichi Sankyo and Merck Announce Global Development and ...
WEBOct 19, 2023 · Collaboration combines Daiichi Sankyo’s proven ADC expertise and DXd technology with Merck’s deep experience in oncology and clinical development capabilities to advance and expand the reach of ADCs for patients across multiple types of cancer